Ekso Bionics to Report Fourth Quarter and Year-End 2015 Financial Results on March 14, 2016
Mar 08, 2016 21:03 pm UTC| Business
RICHMOND, Calif., March 08, 2016 -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it will release financial and business results for the fourth quarter and year-end 2015...
Blue Buffalo Reports Fourth Quarter and Full Year 2015 Results
Mar 08, 2016 21:01 pm UTC| Business
WILTON, Conn., March 08, 2016 -- Blue Buffalo Pet Products, Inc. (the “Company”) (NASDAQ:BUFF), the leading natural pet food company in the United States, today announced its fourth quarter and full year 2015 results. ...
Allscripts and AssistRx Partner to Improve Speed of Prescribing Specialty Medications
Mar 08, 2016 21:01 pm UTC| Business
CHICAGO, March 08, 2016 -- Allscripts (NASDAQ:MDRX) and AssistRx have agreed to a partnership that will focus on technology solutions to accelerate collaboration among providers, payers and life sciences organizations...
Mar 08, 2016 21:01 pm UTC| Business
SAN DIEGO, March 08, 2016 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the...
ZAGG Reports Record Net Sales for 2015, Announces Closing of Merger With mophie
Mar 08, 2016 21:01 pm UTC| Business
Record net sales of $269.3 million compared to $261.6 million in 2014 Gross margins improved to 38% compared to 32% in 2014GAAP earnings per diluted share of $0.54, a 59% increase compared to $0.34 in 2014Adjusted EBITDA...
Reed’s, Inc. Launches First All-Natural Soda Fountain
Mar 08, 2016 21:00 pm UTC| Business
LOS ANGELES, March 08, 2016 -- Reed’s, Inc. (NYSE:REED), the leading maker of craft sodas nationwide announced today they are introducing the first ever all natural Soda Fountain for retailers to be able to dispense...
Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update
Mar 08, 2016 21:00 pm UTC| Business
Significant Progressin Proprietary Development Pipeline and Partnered Programs Initiated Phase 2 Trial of XEN801 in Moderate to Severe Acne; Results Anticipated in Fourth Quarter of 2016 BURNABY, British Columbia, March...